You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm said that sales growth was impacted by immigration headwinds, severe winter weather in the US, and unfavorable order timing in Asia.
The company said revenues in its diagnostics business unit rose 62 percent during the quarter.
The company said test volume rose 87 percent to 186,000 during the quarter.
Lifted by a strong flu season, Cobas Liat PCR placements reached 1,500 systems in the US. Globally, year-over-year sales for the point-of-care system grew 262 percent.
The firm said that it expects to log $500 million in revenues from its Alere rapid diagnostics business in the second quarter.
The company said it had a large uptick in testing revenues during the quarter, including for its AlloSure kidney transplant test, which was launched in October.
Guidance for 2018 placements of ePlex respiratory testing systems is lower than analysts’ estimates, but the firm communicated remedies for adoption challenges.
On a conference call following the release of the earnings, the firm's CEO guided for lower 2018 ePlex placements than had been expected by analysts.
Prompted by an FDA letter requesting additional clinical testing, the firm expects to shut down its development of a babesia blood-donor screening assay.
The company said 571,000 people were screened for colon cancer with its noninvasive Cologuard test in 2017.